All Stories

  1. Design of organoruthenium complexes for nanoparticle functionalization
  2. Comparative solution studies and cytotoxicity of gallium(III) and iron(III) complexes of 3-hydroxy-2(1H)-pyridinones
  3. Periodic DFT modeling and vibrational analysis of silver(I) cyanide complexes of thioureas
  4. Coordination Chemistry of Organoruthenium Compounds with Benzoylthiourea Ligands and their Biological Properties
  5. Structural Modifications of the Antiinflammatory Oxicam Scaffold and Preparation of Anticancer Organometallic Compounds
  6. Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity
  7. Synthesis, characterisation and electronic properties of naphthalene bridged disilanes
  8. Correction to “(Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity Toward Biomolecules”
  9. Hybrid compounds from chalcone and 1,2-benzothiazine pharmacophores as selective inhibitors of alkaline phosphatase isozymes
  10. Understanding the interactions of diruthenium anticancer agents with amino acids
  11. A Bioactive l-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action
  12. Organoruthenium and -osmium Complexes of 2-Pyridinecarbothioamides Functionalized with a Sulfonamide motif: Synthesis, Cytotoxicity and Biomolecule Interaction
  13. (Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity toward Biomolecules
  14. Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action
  15. Anticancer metallodrugs: where is the next cisplatin?
  16. Making organoruthenium complexes of 8-hydroxyquinolines more hydrophilic: impact of a novel l-phenylalanine-derived arene ligand on the biological activity
  17. Organometallics in Cancer Treatment—Non-conventional Structures and Modes of Action
  18. Anticancer Ru( η 6 - p -cymene) complexes of 2-pyridinecarbothioamides: A structure–activity relationship study
  19. Ruthenium Anticancer Agents En Route to the Tumor
  20. Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity
  21. Back Cover: Functionalization of Ruthenium(II)(η6 -p -cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies (ChemPlusChem 6/2017)
  22. Functionalization of Ruthenium(II)(η6 -p -cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies
  23. Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os
  24. Ruthenium Anticancer Agents-From Cisplatin Analogues to Rational Drug Design
  25. Synthesis, X-ray structure, spectroscopic (IR, NMR) analysis and DFT modeling of a new polymeric Zinc(II) complex of cystamine, [Zn(Cym-Cym)Cl2]
  26. Cationic Ru(η6-p-cymene) Complexes of 3-Hydroxy-4-pyr(id)ones - Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents
  27. Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand
  28. Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies
  29. N-(4-Benzoylphenyl)pyridine-2-carbothioamide
  30. Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity
  31. RuII(η6-p-cymene) Complexes of Bioactive 1,2-Benzothiazines: Protein Binding vs. Antitumor Activity
  32. Half-Sandwich Ruthenium(II) Biotin Conjugates as Biological Vectors to Cancer Cells
  33. Traditional Uses, Phytochemistry, and Pharmacology ofOlea europaea(Olive)
  34. Synthesis and characterization of silver(I) complexes of thioureas and thiocyanate: crystal structure of polymeric (1,3-diazinane-2-thione)thiocyanato silver(I)
  35. Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity
  36. Development of anticancer agents: wizardry with osmium
  37. Anticancer Ruthenium(η6-p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives
  38. Aromaticities of azines relative to benzene; a theoretical approach through the dimethyldihydropyrene probe
  39. RutheniumII(η6-arene) Complexes of Thiourea Derivatives: Synthesis, Characterization and Urease Inhibition
  40. Extraction of Pb(II) from water samples by ionic liquid-modified silica sorbents
  41. Aromaticity of azines through dyotropic double hydrogen transfer reaction
  42. Copper Complexes of Bioactive Ligands with Superoxide Dismutase Activity
  43. Solution equilibrium studies on anticancer ruthenium(II)–η6-p-cymene complexes of 3-hydroxy-2(1H)-pyridones
  44. Theoretical insight of polypyrrole ammonia gas sensor
  45. Novel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents
  46. Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes
  47. Organometallic Ruthenium and Osmium Compounds of Pyridin-2- and -4-ones as Potential Anticancer Agents
  48. Biomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins
  49. Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules
  50. Synthesis of [RuII(η6-p-cymene)(PPh3)(L)Cl]PF6 complexes with carbohydrate-derived phosphites, imidazole or indazole co-ligands
  51. Pyrone derivatives and metals: From natural products to metal-based drugs
  52. From hydrolytically labile to hydrolytically stable RuII–arene anticancer complexes with carbohydrate-derived co-ligands
  53. Is the Reactivity of M(II)−Arene Complexes of 3-Hydroxy-2(1H)-pyridones to Biomolecules the Anticancer Activity Determining Parameter?
  54. Osmium(ii)–versus ruthenium(ii)–arene carbohydrate-based anticancer compounds: similarities and differences
  55. Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)?(η6-Arene) Complexes
  56. In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands
  57. Bis(cyanido-κC)(ethane-1,2-diamine-κ2N,N′)silver(II)
  58. Poly[bis(μ2-cyanido)-κ2C:N;κ2N:C-(μ2-N,N,N′,N′-tetramethylthiourea-κ2S:S)disilver(I)]